Saptarshi Sinha and Chanakya Nath Kundu*

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, India

*Corresponding Author: Chanakya Nath Kundu, Professor, Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, India.

Received: December 29, 2022; Published: March 01, 2023

Breast cancer is regarded as the most common type of malignancy affecting women worldwide. In 2020, it became the most commonly diagnosed cancer, surpassing lung and other types of cancer [1]. Currently, the different breast cancer treatment options include chemotherapy, radiotherapy, and hormone therapy. But the cancer cells have devised ways to bypass the therapeutic effects of these treatment strategies [2]. Moreover, the chemotherapeutic drugs have been found to exhibit certain adverse effects, including high cytotoxicity, off-target effect, development of chemoresistance, and reduced bioavailability [3]. Hence, it is now imperative for the cancer biologists to conduct extensive research and develop novel chemotherapeutic regimens that will minimize the side effects and also effectively kill the breast cancer cells.

References

1. Sung Hyuna., et al. "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: A Cancer Journal for Clinicians3 (2021): 209-249.
2. Ji Xiwei., et al. "Chemoresistance mechanisms of breast cancer and their countermeasures”. Biomedicine and Pharmacotherapy 114 (2019): 108800.
3. Senapati Sudipta., et al. "Controlled drug delivery vehicles for cancer treatment and their performance”. Signal Transduction and Targeted Therapy1 (2018): 1-19.
4. Kelley Mark R., et al. "Targeting DNA repair pathways for cancer treatment: what’s new?”. Future Oncology7 (2014): 1215-1237.
5. Rauf Abdur., et al. "Resveratrol as an anti-cancer agent: A review”. Critical Reviews in Food Science and Nutrition 9 (2018): 1428-1447.
6. Wallerath Thomas., et al. "Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase”. Circulation 13 (2002): 1652-1658.
7. Ko Jeong-Hyeon., et al. "The role of resveratrol in cancer therapy”. International Journal of Molecular Sciences 12 (2017): 2589.
8. Leone, Stefano., et al. "Resveratrol induces DNA double-strand breaks through human topoisomerase II interaction”. Cancer Letters2 (2010): 167-172.
9. Le Corre, Ludovic., et al. "Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines”. Clinica Chimica Acta1-2 (2004): 115-121.
10. Scully, Ralph., et al. "DNA double-strand break repair-pathway choice in somatic mammalian cells”. Nature Reviews Molecular Cell biology 11 (2019): 698-714.
11. Ko Hui Ling and Ee Chee Ren. "Functional aspects of PARP1 in DNA repair and transcription”. Biomolecules 4 (2012): 524-548.
12. McCabe Nuala., et al. "Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition”. Cancer Research 16 (2006): 8109-8115.
13. Sinha Saptarshi., et al. "Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway”. Experimental Cell Research 1 (2022): 113338.

Citation

Citation: Saptarshi Sinha and Chanakya Nath Kundu. “Red Wine Polyphenol Resveratrol Reduces Breast Cancer Progression and PARP Inhibitor Olaparib Efficiently Enhances its Anti-cancer Action" Acta Scientific Cancer Biology 7.2 (2023): 01-02.

Copyright

Copyright: © 2022 Saptarshi Sinha and Chanakya Nath Kundu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.